Who are Traditional Cryoprecipitate's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Pathogen-Reduced Plasma, FFP, Dry plasma, Transfusion of blood products, Pathogen-Reduced Cryoprecipitate, MIS.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/traditional-cryoprecipitate.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Traditional Cryoprecipitate — Competitive Intelligence Brief

Traditional Cryoprecipitate (Traditional Cryoprecipitate) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Blood product; clotting factor concentrate. Area: Hematology; Hemostasis and Thrombosis.

marketed Blood product; clotting factor concentrate Fibrinogen, Factor VIII, von Willebrand factor, Fibronectin, Factor XIII Hematology; Hemostasis and Thrombosis Biologic Live · refreshed every 30 min

Target snapshot

Traditional Cryoprecipitate (Traditional Cryoprecipitate) — Weill Medical College of Cornell University. Cryoprecipitate is a blood product concentrate that replaces deficient clotting factors and fibrinogen to restore hemostatic function in patients with bleeding disorders.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Traditional Cryoprecipitate TARGET	Traditional Cryoprecipitate	Weill Medical College of Cornell University	marketed	Blood product; clotting factor concentrate	Fibrinogen, Factor VIII, von Willebrand factor, Fibronectin, Factor XIII
Pathogen-Reduced Plasma	Pathogen-Reduced Plasma	Coalition for National Trauma Research	marketed	Blood product / Plasma derivative
FFP	FFP	Erasmus Medical Center	marketed	Blood product / Plasma derivative
Dry plasma	Dry plasma	Vastra Gotaland Region	marketed	Blood product / Plasma derivative
Transfusion of blood products	Transfusion of blood products	Fundacion Clinica Valle del Lili	marketed	Blood product transfusion
Pathogen-Reduced Cryoprecipitate	Pathogen-Reduced Cryoprecipitate	Weill Medical College of Cornell University	marketed	Blood product / Hemostatic agent
MIS	MIS	Blood Transfusion Centre of Slovenia	marketed	Plasma-derived immunoglobulin preparation or blood product

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Blood product; clotting factor concentrate class)

Weill Medical College of Cornell University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Traditional Cryoprecipitate — Competitive Intelligence Brief. https://druglandscape.com/ci/traditional-cryoprecipitate. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab